I am just tech savvy enough to know that the marke
Post# of 30028
Posted On: 03/27/2015 11:04:51 AM
I am just tech savvy enough to know that the market is unimpressed with pre-clinical MANF, an Eltoprazine Phase 2b clinical trial IND, ESS, LymPro/Georgetown, the MS diagnostic, and Phenoguard.
Gerald's plan A for increasing shareholder value didn't work in the first half of 2014. His plan B didn't work in July of 2014. His plan C didn't work for year end. And his plan D hasn't worked in Q1 of 2015.
We're going to run out of the alphabet before any of Gerry's plans work! That's what all the "tech indicators" I've been watching have indicated.
Your PLATITUDES about being "long term" become POINTLESS unless they're backed up by the company's short term PERFORMANCE! Randall Grimes hasn't been able to get any non-dilutive financing or grants in over 1.5 years! Big Pharma isn't chomping at the bit to use LymPro. And the market doesn't seem to care about Eltoprazine or ESS. MANF is still a long ways off to be able to help us in the next year.
The Commissiongs and Rubenfeld knew this from the beginning, but they had to put together a plausible song and dance to get investors excited during the many longs years required to get MANF to market. But Gerry's song and dance routines are old hat now. Everyone's seen it over and over again and are waiting now from something more substantial.
I don't know if Gerry has anything substantial in his arsenal in the near term.
Gerald's plan A for increasing shareholder value didn't work in the first half of 2014. His plan B didn't work in July of 2014. His plan C didn't work for year end. And his plan D hasn't worked in Q1 of 2015.
We're going to run out of the alphabet before any of Gerry's plans work! That's what all the "tech indicators" I've been watching have indicated.
Your PLATITUDES about being "long term" become POINTLESS unless they're backed up by the company's short term PERFORMANCE! Randall Grimes hasn't been able to get any non-dilutive financing or grants in over 1.5 years! Big Pharma isn't chomping at the bit to use LymPro. And the market doesn't seem to care about Eltoprazine or ESS. MANF is still a long ways off to be able to help us in the next year.
The Commissiongs and Rubenfeld knew this from the beginning, but they had to put together a plausible song and dance to get investors excited during the many longs years required to get MANF to market. But Gerry's song and dance routines are old hat now. Everyone's seen it over and over again and are waiting now from something more substantial.
I don't know if Gerry has anything substantial in his arsenal in the near term.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼